Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression

American Journal of Psychiatry

Volumn 173, Issue 2, 2016, Pages 107-111

  Fawcett, Jan ^a   Rush, A John ^a   Vukelich, John ^a   Diaz, Shanna H ^a   Dunklee, Lucas ^a   Romo, Paul ^a   Yarns, Brandon C ^a   Escalona, Rodrigo ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; NORTRIPTYLINE; PRAMIPEXOLE; PREDNISONE; VENLAFAXINE; BENZOTHIAZOLE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BEDTIME DOSAGE; BIPOLAR DEPRESSION; BODY WEIGHT DISORDER; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DELUSION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; HYPERSEXUALITY; INSOMNIA; LOW DRUG DOSE; LUNG INFECTION; MAJOR DEPRESSION; MALE; NAUSEA; OUTCOME ASSESSMENT; PANIC; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; RETREATMENT; SEXUAL AROUSAL DISORDER; SOMNOLENCE; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VISUAL HALLUCINATION; WEIGHT GAIN; WEIGHT REDUCTION; BIPOLAR DISORDER; CASE REPORT; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; BENZOTHIAZOLES; BIPOLAR DISORDER; BUPROPION; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTRIPTYLINE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENLAFAXINE HYDROCHLORIDE;

EID: 84957664190     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.15060788     Document Type: Article

References (36)

1. TriveDi MH, Rush AJ, Wisniewski SR, et al: Factors associated with health-related quality of life among outpatientswithmajor depressive disorder: a STARD report. J Clin Psychiatry 2006; 67:185-195
2. Rush AJ, TriveDi MH, Wisniewski SR, et al: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry 2006; 163:1905-1917
3. Rush AJ, Thase ME, Dubé S: Research issues in the study of difficultto-treat depression. Biol Psychiatry 2003; 53:743-753
4. Bowden Cl, PerlisRH,ThaseME,et al:Aimsand results of theNIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). CNS Neurosci Ther 2012; 18:243-249
5. Rush AJ, George MS, Sackeim HA, et al: Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000; 47:276-286
6. Cusin C, Iovieno N, Iosifescu DV, et al: A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatmentresistantmajordepressivedisorder. JClinPsychiatry2013;74:e636-e641
7. Shelton RC, Osuntokun O, Heinloth AN, et al: Therapeutic options for treatment-resistant depression. CNS Drugs 2010; 24:131-161
8. Thase ME, Rush AJ: Treatment-resistant depression, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York, Raven Press, 1995, pp 1081-1097
9. RussellJM,HawkinsK, OzminkowskiRJ, et al:Thecost consequences of treatment-resistant depression. J Clin Psychiatry 2004; 65:341-347
10. Dunlop BW, Nemeroff CB: The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64:327-337
11. Fawcett J, Siomopoullos V: Dextroamphetamine response as a possible predictor of improvement with tricyclic therapy in depression. Arch Gen Psychiatry 1971; 25:247-255
12. Fawcett J, Maas JW, Dekirmenjian H: Depression and MHPG excretion: response to dextroamphetamine and tricyclic antidepressants. Arch Gen Psychiatry 1972; 26:246-251
13. Aiken CB: Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007; 68:1230-1236
14. Stahl SM, Felker A:Monoamine oxidase inhibitors: amodern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13:855-870
15. Fawcett J: Why aren't MAOIs used more often? J Clin Psychiatry 2009; 70:139-140
16. Candy M, Jones L, Williams R, et al: Psychostimulants for depression. Cochrane Database Syst Rev 2008; 16:CD006722
17. Uher R, Perlis RH, Henigsberg N, et al: Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidencefor interest-activity symptoms. PsycholMed2012;42:967-980
18. Fawcett J, Kravitz HM, Zajecka JM, et al: CNS stimulant potentiation of monamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991; 11:127-132
19. Treadway MT, Zald DH: Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 2011; 35:537-555
20. Marcus RN, McQuade RD, Carson WH, et al: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28:156-165
21. Berman RM, FavaM, Thase ME, et al: Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14:197-206
22. Lemke MR, Brecht HM, Koester J, et al: Effects of the dopamine agonist pramipexole on depression, anhedonia, and motor functioning in Parkinson's disease. J Neurol Sci 2006; 248:266-270
23. Bega D, WuSS, Pei Q, et al: Recognition and treatment of depressive symptoms in Parkinson's disease: the NPF dataset. J Parkinsons Dis 2014; 4:639-643
24. Loas G, Krystkowiak P, Godefroy O: Anhedonia in Parkinson's disease: an overview. J Neuropsychiatry Clin Neurosci 2012; 24:444-451
25. Miura S, Kida H, Nakajima J, et al: Anhedonia in Japanese patients with Parkinson's disease: analysis using the Snaith-Hamilton Pleasure Scale. Clin Neurol Neurosurg 2012; 114:352-355
26. Barone P, ScarzellaL,Marconi R, et al: Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253:601-607
27. Goldberg JF, BurDick KE, EnDick CJ: Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added tomood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161:564-566
28. Corrigan MH, Denahan AQ, Wright CE, et al: Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11:58-65
29. Iyo M, Yamasaki T: The detection of age-related decrease of dopamine D1, D2,and serotonin5-HT2receptors in livinghumanbrain. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17:415-421
30. Wang GJ, Volkow ND, Logan J, et al: Evaluation of age-related changes in serotonin5-HT2anddopamineD2receptor availability in human subjects. Life Sci 1995; 56:249-253
31. Rabinak CA, Nirenberg MJ: Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67:58-63
32. Joyce JN, Millan MJ: Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Curr Opin Pharmacol 2007; 7: 100-105
33. Leggio GM,Salomone S, Bucolo C, et al: Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 2013; 719:25-33
34. Schulte-Herbrüggen O, Vogt MA, Hörtnagl H, et al: Pramipexole is active in depression tests and modulates monoaminergic transmission, but not brain levels ofBDNFin mice. Eur J Pharmacol 2012; 677:77-86
35. ConwayCR, Chibnall JT, CummingP, et al: Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminaryPETstudy. Psychiatry Res 2014; 221:231-239
36. Lammers CH, Diaz J, Schwartz JC, et al: Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000; 5:378-388